Sales of Curosurf[R] (poractant alfa
), a pulmonary surfactant, exceeded [euro]200m, growing by 14.4% over 2014 and confirming its global importance as a potentially life-saving drug.
Compliations among premature neonates treated with beractant and poractant alfa. Indian J Pediatr 2010; 77: 751-4.
A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
27 January 2012 - Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical group focused on products for respiratory conditions, said that a new analysis revealed significant benefits in mortality rate and the need for redosing in the treatment of neonatal respiratory distress syndrome (RDS) with the company's CUROSURF (poractant alfa
) Intratracheal Suspension.
The biological surfactant preparation Curosurf (poractant alfa
) was derived from minced porcine lung extracts, and its indications followed similar risk profiles as noted in the biologicals above.
EVIDENCE FOR A MORTALITY BENEFIT FOR PORACTANT ALFA
* Poractant alfa
(Curosurf) for respiratory distress syndrome.
A randomized, multicenter masked comparison trial of poractant alfa
(Curosurf ) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Examples of natural surfactant include Beractant (Survanta), Poractant Alfa
(Curosurf), and Clafactant (Infasurf)